UBS Group Has Lowered Expectations for Kymera Therapeutics (NASDAQ:KYMR) Stock Price

Kymera Therapeutics (NASDAQ:KYMR - Free Report) had its target price decreased by UBS Group from $80.00 to $74.00 in a research report released on Monday morning, Benzinga reports. UBS Group currently has a buy rating on the stock.

Several other brokerages have also recently weighed in on KYMR. B. Riley lifted their price target on Kymera Therapeutics from $31.00 to $36.00 and gave the company a "neutral" rating in a research report on Tuesday, July 9th. Oppenheimer increased their price target on shares of Kymera Therapeutics from $52.00 to $56.00 and gave the stock an "outperform" rating in a report on Friday, September 27th. Truist Financial reaffirmed a "buy" rating and set a $53.00 price objective (down previously from $54.00) on shares of Kymera Therapeutics in a research note on Friday. Guggenheim boosted their price objective on shares of Kymera Therapeutics from $45.00 to $52.00 and gave the stock a "buy" rating in a report on Friday. Finally, Morgan Stanley raised their price objective on Kymera Therapeutics from $34.00 to $45.00 and gave the stock an "equal weight" rating in a research note on Wednesday, August 14th. Four investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $50.93.

Kymera Therapeutics Trading Up 1.3 %

Shares of KYMR traded up $0.60 during mid-day trading on Monday, reaching $47.07. 303,479 shares of the stock traded hands, compared to its average volume of 596,018. The firm has a fifty day moving average price of $46.98 and a 200 day moving average price of $40.83. Kymera Therapeutics has a 1 year low of $13.85 and a 1 year high of $53.27. The company has a market cap of $2.91 billion, a price-to-earnings ratio of -20.12 and a beta of 2.21.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last posted its quarterly earnings data on Thursday, October 31st. The company reported ($0.82) earnings per share for the quarter, beating analysts' consensus estimates of ($0.83) by $0.01. The company had revenue of $3.74 million during the quarter, compared to analyst estimates of $10.34 million. Kymera Therapeutics had a negative return on equity of 28.05% and a negative net margin of 191.26%. The firm's revenue for the quarter was down 20.9% on a year-over-year basis. During the same quarter last year, the company earned ($0.90) EPS. On average, sell-side analysts anticipate that Kymera Therapeutics will post -2.85 EPS for the current year.

Insider Activity

In other Kymera Therapeutics news, Director Pamela Esposito sold 13,500 shares of the firm's stock in a transaction on Tuesday, September 17th. The shares were sold at an average price of $48.28, for a total transaction of $651,780.00. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In other Kymera Therapeutics news, Director Pamela Esposito sold 13,500 shares of the business's stock in a transaction that occurred on Tuesday, September 17th. The shares were sold at an average price of $48.28, for a total transaction of $651,780.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Jeffrey W. Albers sold 5,000 shares of Kymera Therapeutics stock in a transaction on Monday, August 26th. The stock was sold at an average price of $49.10, for a total transaction of $245,500.00. The disclosure for this sale can be found here. Corporate insiders own 15.82% of the company's stock.

Institutional Trading of Kymera Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Price T Rowe Associates Inc. MD increased its position in Kymera Therapeutics by 18.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 6,332,012 shares of the company's stock worth $254,548,000 after purchasing an additional 996,300 shares during the period. Vanguard Group Inc. grew its holdings in shares of Kymera Therapeutics by 19.2% during the 1st quarter. Vanguard Group Inc. now owns 4,767,050 shares of the company's stock worth $191,635,000 after purchasing an additional 769,486 shares in the last quarter. Avoro Capital Advisors LLC boosted its holdings in shares of Kymera Therapeutics by 3.0% in the 1st quarter. Avoro Capital Advisors LLC now owns 3,888,888 shares of the company's stock valued at $156,333,000 after purchasing an additional 113,888 shares in the last quarter. Artal Group S.A. increased its position in Kymera Therapeutics by 19.6% during the 1st quarter. Artal Group S.A. now owns 3,027,135 shares of the company's stock worth $121,691,000 after purchasing an additional 496,400 shares in the last quarter. Finally, Jennison Associates LLC bought a new position in Kymera Therapeutics in the 1st quarter valued at approximately $17,122,000.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.